Skip to content

US · INAB · BIOTECHNOLOGY

IN8bio, Inc. (INAB) intrinsic value and stock valuation

$0.76as of 2026-11-21 · Mkt cap 9.38M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

IN8bio, Inc. DCF and intrinsic value

InvestorsCraft values INAB with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from INAB’s statements →

IN8bio, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology New York City, NY 10118 in8bio.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$0.00
20182025
Net income
-$-19.44M
20182025
Free cash flow
-$-12.71M
20182025
Total equity
$27.6M+8.5% 5y CAGRd
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-19.86M-$-30.44M-$-30.34M-$-28.52M-$-14.65M
Net income-$-19.44M-$-30.44M-$-30.01M-$-28.52M-$-14.65M
EPSd-$-4.45M-$-17.1M-$-30.01M-$-40.74M-$-23.25M
Operating cash flow-$-12.71M-$-24.15M-$-23.34M-$-24.12M-$-13.51M
Capital expenditure$0.00-$-100K-$-600K-$-3.71M-$-310K
Free cash flow-$-12.71M-$-24.25M-$-23.94M-$-27.83M-$-13.82M
Total assets$32.3M$20.9M$33.7M$33M$42.2M
Total debt$2.78M$5.03M$4.89M$5.87M$2.41M
Net debt-$-24.31M-$-6.09M-$-16.39M-$-12.31M-$-34.61M
Total equity$27.6M$14.5M$24.9M$22.7M$38.2M
Cash and short-term investments$27.1M$11.1M$21.3M$18.2M$37M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$2.5M$0.00$2.5M$0.00$0.00
Gross profit-$-2.5M$0.00-$-2.5M$0.00$0.00
Research and development expenses$10.2M$17M$16.8M$14.1M$7.35M
Selling, general and administrative expenses$9.65M$12.6M$13.5M$14.5M$7.31M
Other expenses-$-2.5M$840K-$-2.5M$0.00$0.00
Operating expenses$17.4M$30.4M$27.8M$28.5M$14.7M
Cost and expenses$19.9M$30.4M$30.3M$28.5M$14.7M
Interest income$420K$230K$0.00$0.00$0.00
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$2.5M$2.65M$2.5M$1.1M$790K
Ebitda-$-16.94M-$-26.94M-$-27.51M-$-27.42M-$-13.87M
Operating income-$-19.86M-$-30.44M-$-30.34M-$-28.52M-$-14.65M
Total other income/expenses, net$420K$0.00$330K$0.00$0.00
Income before tax-$-19.44M-$-30.44M-$-30.01M-$-28.52M-$-14.65M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-19.44M-$-30.44M-$-30.01M-$-28.52M-$-14.65M
Weighted average shares outstanding$4.37M$1.78M$1M$700K$630K
Weighted average diluted shares outstanding$4.37M$1.78M$1M$700K$630K
Balance sheet
20252024202320222021
Cash and short-term investments$27.1M$11.1M$21.3M$18.2M$37M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$27.9M$12.6M$24.6M$22.2M$39M
Property, plant and equipment, net$4.04M$7.83M$8.57M$10.3M$2.83M
Goodwill and intangible assets$0.00$0.00$0.00$130K$0.00
Long-term investments$220K$270K$260K$250K$0.00
Total non-current assets$4.4M$8.37M$9.08M$10.8M$3.24M
Total assets$32.3M$20.9M$33.7M$33M$42.2M
Accounts payable$310K$390K$920K$2.09M$400K
Short-term debt$1.22M$1.65M$1.51M$1.39M$630K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$3.16M$3.08M$5.39M$5.82M$2.26M
Long-term debt$1.56M$3.38M$3.38M$4.49M$1.78M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$1.56M$3.38M$3.38M$4.49M$1.78M
Capital lease obligations$1.22M$5.03M$4.89M$5.87M$2.41M
Total liabilities$4.72M$6.47M$8.77M$10.3M$4.04M
Common stock$10K$10K$0.00$0.00$0.00
Retained earnings-$-141.1M-$-121.66M-$-91.22M-$-61.21M-$-32.69M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$27.6M$14.5M$24.9M$22.7M$38.2M
Total investments$220K$270K$260K$250K$0.00
Total debt$2.78M$5.03M$4.89M$5.87M$2.41M
Net debt-$-24.31M-$-6.09M-$-16.39M-$-12.31M-$-34.61M
Cash flow statement
20252024202320222021
Net income-$-19.44M-$-30.44M-$-30.01M-$-28.52M-$-14.65M
Depreciation and amortization$1.77M$2.65M$2.5M$1.1M$790K
Stock-based compensation$3.19M$5M$4.37M$3.47M$2.19M
Change in working capital$1.04M-$-1.41M-$-200K-$-170K-$-1.84M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-80K-$-540K-$-980K$1.51M-$-320K
Net cash provided by operating activities-$-12.71M-$-24.15M-$-23.34M-$-24.12M-$-13.51M
Investments in property, plant and equipment$0.00-$-100K-$-600K-$-3.71M-$-310K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00-$-190K-$-600K-$-3.71M-$-310K
Common stock issued$29.3M$9.94M$27.8M$9.54M$36.3M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$28.6M$14.2M$27M$8.99M$33M
Net change in cash$15.9M-$-10.15M$3.1M-$-18.84M$19.1M
Cash at end of period$27.3M$11.4M$21.3M$18.4M$37.3M
Operating cash flow-$-12.71M-$-24.15M-$-23.34M-$-24.12M-$-13.51M
Capital expenditure$0.00-$-100K-$-600K-$-3.71M-$-310K
Free cash flow-$-12.71M-$-24.25M-$-23.94M-$-27.83M-$-13.82M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About IN8bio, Inc.

        IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phase I clinical study for glioblastoma and other solid tumor malignancies. Additionally, INB-100, an allogeneic (donor-derived) candidate, is also in a Phase I clinical trial, aiming to treat acute leukemia patients undergoing hematopoietic stem cell transplantation. Further development includes preclinical programs, INB-400 and INB-300, which are designed to address a range of solid tumor cancers. Established in 2016, the company initially operated as Incysus Therapeutics, Inc. before changing its name to IN8bio, Inc. in August 2020. Its corporate headquarters are located in New York, New York.

        CEO
        William T.
        Employees
        17
        Beta
        0.28

        Explore

        Frequently asked questions

        What is the intrinsic value of IN8bio, Inc. (INAB)?

        InvestorsCraft does not currently publish an intrinsic value for INAB. How the IC value is calculated.

        Is INAB undervalued?

        InvestorsCraft does not publish an undervaluation signal for INAB at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.